The dvm360 editorial team is counting down our Top 20 news stories and articles of the year, from January 1, 2024, to ...

Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Higher frequency of antibiotic use was not associated with dementia or cognitive impairment; neither was long-term use. No ...

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture Justice Kyra Harris Bolden ...

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...